Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06964165 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
A Phase 2 study, sponsored by Tesaro.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT06964165 is a Phase 2 study that was terminated before completion, run by Tesaro. The registered enrollment target is 36 participants.
The verdict
NCT06964165, a Phase 2 study, was terminated before completion, sponsored by Tesaro.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06964165
The ClinicalTrials.gov registry entry for NCT06964165 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT06964165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06964165 about?
NCT06964165 is a clinical study titled "A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)". The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)
What is the current status of trial NCT06964165?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-04-14. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT06964165?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Niraparib (DRUG).
Who is sponsoring clinical trial NCT06964165?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.